Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.
Metrics to compare | IBTb | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIBTbPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.9x | −6.6x | −0.6x | |
PEG Ratio | 1.33 | −0.14 | 0.00 | |
Price/Book | 2.8x | 6.4x | 2.6x | |
Price / LTM Sales | 113,429.4x | 20.1x | 3.1x | |
Upside (Analyst Target) | - | 49.0% | 53.0% | |
Fair Value Upside | Unlock | −9.8% | 8.0% | Unlock |